Andrew Knudten, MS, MBA

Chief Operating Officer

With an MS in Cell Biology and Genetics, Andrew leverages his extensive experience in developing and successfully commercializing gene therapy treatments including manufacturing, process development and supply chain know-how.

Formerly of AveXis, Hospira, Novartis, and Amgen.